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Abstract
Introduction Breast-cancer-related lymphedema affects
∼25% of breast cancer (BC) survivors and may impact
use of the upper limb during activity. The purpose of this
study is to compare upper extremity (UE) impairment and
activity between women with and without lymphedema
after BC treatment.
Methods 144 women post BC treatment completed demo-
graphic, symptom, and Disability of Arm-Shoulder-Hand
(DASH) questionnaires. Objective measures included Pur-
due pegboard, finger-tapper, Semmes-Weinstein monofila-
ments, vibration perception threshold, strength, range of
motion (ROM), and volume.
Results Women with lymphedema had more lymph nodes
removed (p<.001), more UE symptoms (p<.001), higher
BMI (p=.041), and higher DASH scores (greater limitation)
(p<.001). For all participants there was less strength (elbow
flexion, wrist flexion, grip), less shoulder ROM, and
decreased sensation at the medial upper arm (p<.05) in
the affected UE. These differences were greater in women
with lymphedema, particularly in shoulder abduction ROM
(p<.05). Women with lymphedema had bilaterally less
elbow flexion strength and shoulder ROM (p<.05). Past
diagnosis of lymphedema, grip strength, shoulder abduction
ROM, and number of comorbidities contributed to the
variance in DASH scores (R
2 of 0.463, p<.001).
Implications for cancer survivors UE impairments are
found in women following treatment for BC. Women with
lymphedema have greater UE impairment and limitation in
activities than women without. Many of these impairments
are amenable to prevention measures or treatment, so early
detection by health care providers is essential.
Keywords Lymphedema.Breastcancer.Movement.
Impairment.Upperextremity
Introduction
Treatment for breast cancer has improved dramatically over
thelasttwodecades.Whilethesetreatmentshavesignificantly
increasedthe 5 yearsurvivalrates,theyare not without lasting
adverse effects. Currently there are over two million breast
cancersurvivors in theUnitedStates[1–3] and a considerable
number of these women have or will develop complications,
such as lymphedema or post-treatment pain, as a result of
their treatment. It is our hypothesis that following breast
cancer treatment, women will demonstrate upper extremity
physical impairment, and these impairments will contribute
to limitations in activities requiring use of the affected upper
limb. Moreover, we hypothesize that those women who
develop breast-cancer-related lymphedema will demonstrate
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Breast cancer treatments include surgery, radiation, and
systemic therapies and each is associated with short and
long term sequelae. Chemotherapy, for example, is known
to induce neuropathy, impaired concentration and memory,
and generalized fatigue [4–6]. Chemotherapy plus radiation
therapy after axillary node dissection have been associated
with chronic pain, particularly in the ipsilateral arm [7].
Local treatments such as axillary dissection or radiation
therapy following surgical excision of the tumor have been
associated with regional physical dysfunction and increased
incidence of long term arm morbidity, including impaired
shoulder mobility and lymphedema [8, 9]. For example,
shoulder range of motion is limited in up to 45% of patients
who have sentinel node biopsy, and 86% of patients who
have undergone axillary clearance [10].
Breast-cancer-related lymphedema develops in 5% to
42% of women following breast cancer treatment, depen-
dent, in part, on the aggressiveness of treatment [11, 12].
Lymphedema is the accumulation of protein rich interstitial
fluid as a result of impaired lymphatic function [13].
Lymphedema related to breast cancer treatment may result
from surgical removal of lymph nodes and lymphatic
drainage pathways. Further damage to the lymphatic system
may result from soft tissue fibrosis following inflammation,
infection, or radiation. Of significant importance to patients,
breast-cancer-related lymphedema is an impairment which
can adversely affect upper extremity function [14–16].
Though several recent studies have investigated upper
extremity function in women following breast cancer
treatment, none have specifically compared objective
measures of upper extremity physical impairments in
women with lymphedema and those without. The primary
aim of the present study is to compare differences in upper
extremity impairment between women who have developed
lymphedema after breast cancer treatment and those who
have not developed lymphedema. Secondarily, we seek to
determine the contribution of impairments to self-reported
limitations in activities requiring use of the affected upper
extremity. Definitions of impairment and activity are based
on the World Health Organization’s International Classifi-
cation of Functioning, Disability and Health Model.
Impairments describe physical limitations in body struc-
tures and physiological functions, and activity limitations
describe difficulties executing a task or action [17].
Many of the complications arising from breast cancer
treatment go unrecognized and few of these women are
referred for rehabilitation [18]. If there are known and
predictable impairments in women after breast cancer
treatment, then early assessment and rehabilitation interven-
tions can be implemented to decrease pain, diminish losses in
flexibility and strength, and minimize restrictions in activity.
Methods
Participants
Women, with and without lymphedema, who had completed
active breast cancer treatment at least 6 months previously,
were recruited. The women were required to be at least
18 years of age, and able to read, speak, and understand
English. Women were excluded for bilateral breast cancer,
current upper extremity infection, lymphangitis, pre-existing
lymphedema, pre-existing neuromuscular or musculoskeletal
conditions that would affect local upper extremity testing, or
current recurrence of breast cancer. Study participants were
recruited through the National Lymphedema Network web-
site,SanFranciscoBayareahospitals,SanFranciscoBayarea
breast cancer or lymphedema support groups, and breast
cancer conferences.
One hundred and forty eight women completed testing.
Of those, three were found to have bilateral mastectomies
and one had a total shoulder replacement. These four were
excluded from data analysis. The study was approved by
the UCSF Committee on Human Research and the Clinical
and Translational Science (CTSI) Clinical Research Center
Advisory Committee. Written informed consent was
obtained from all participants prior to testing.
Procedures
This study utilized a cross-sectional design. All participants
attended a single evaluation session, during which all
testing occurred. Both upper extremities were assessed.
Testing was completed by one investigator (BS), a physical
therapist with over 20 years of experience. All testing was
performed in the UCSF CTSI Clinical Research Center.
Fine motor skills were assessed using the standardized
Purdue Pegboard (North Coast Medical, Morgan Hill, CA)
and the Finger Tapper Test (Psychological Assessment
Resources, Inc, Lutz, FL). Strength was assessed using
hand held dynamometers. Participants were instructed to
squeeze with maximal effort for the grip tests. Strength
scores were obtained for shoulder abduction, elbow flexion,
and wrist flexion using the MicroFET2 dynamometer
(Hoggan MicroFET2 Muscle Tester, Model 7477, Pro
Med Products, Atlanta, GA). Three grip tests were
performed: full grip using a hand dynamometer (North
Coast Medical, Morgan Hill, CA), key grip (lateral
opposition) using a pinch gauge (North Coast Medical,
Morgan Hill, CA), and pinch grip (terminal opposition or 3-
point chuck) using the MicroFET2. Three trials of each
strength test were performed, and a mean was calculated for
each test. Additionally, a combined strength score was
calculated as the sum of all strength scores for each upper
extremity.
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(ROM) of the upper extremities. Shoulder flexion, shoulder
abduction, shoulder external rotation, elbow flexion and
extension, wrist flexion and extension, and flexion of the
proximal interphalangeal joint of digit two were measured
following standardized procedures reported by Norkin [19].
In addition to individual joint measurements, an overall
summed ROM score was calculated for each upper
extremity.
Semmes-Weinstein monofilaments (North Coast Medi-
cal, Morgan Hill, CA) were used to assess tactile sensitivity
of the upper extremities. Test locations were the inner and
outer aspects of the arm and forearm, the dorsal aspect of
first web space of the hand, the radial aspect of the 2nd
digit distal phalanx, and the ulnar aspect of the 5th digit
distal phalanx. Each region was tested beginning with the
smallest diameter monofilament (2.83; 0.07 g force) and
progressed to successively larger diameter monofilaments,
until 5 of 5 correct responses were obtained. Vibration
Perception Threshold (VPT) was determined using the Bio-
Thesiometer (Bio-Medical Instrument Company, Newbury,
Ohio). The pad of each distal phalanx, the radial styloid, and
medial epicondylewere assessed. The Bio-Thesiometerprobe
was placed on the test area and the amplitude increased from
zero until the participant reported feeling vibration.
Circumferential assessment and bioimpedance were
employed to objectively assess upper extremity limb
volume. A flexible tape measure was used to measure
circumference of each upper extremity at the ulnar styloid,
designated as “0” centimeters, and at 10 cm intervals
proximal to “0” to a maximum of 40 cm. Hand circumfer-
ence was measured at the metacarpophalangeal joints and
2 cm proximally. Volume was calculated from circumfer-
ence measures using the formula for volume of a truncated
cone, V ¼ 1=12Π
P
hC 1
2 þ C1C2 þ C2
2   
, where h is the
length of each measured segment and C is the circumfer-
ence at each end of that segment [20]. The Impedimed
measurement system (SPF7, Garden City, Australia) was
used to measure upper extremity impedance to an alternat-
ing electrical current which provided information about
fluid distribution in specific regions of the body. Electrodes
were placed on the dorsum of the hands, wrists, feet and
ankles. The participants were instructed to lie supine for
10 min with no pillows, arms at sides and lower extremities
flat and slightly abducted [21].
A demographic questionnaire was used to collect
information on age, health, income, ethnicity, menopausal
status, performance and activity status, occupation, and
health status. Information regarding comorbidities was
obtained. Twelve comorbidities were included in the
comorbidity listing: heart disease, high blood pressure,
lung disease, diabetes, stomach disease or ulcer, urinary
tract disorders/kidney disease, liver or gallbladder disease,
anemia or other blood disease, depression, osteoarthritis,
rheumatoid arthritis, and back pain/problems. Additional
questionnaires were completed by the participants to collect
information regarding symptoms in the affected breast,
symptoms in the upper extremity on the side of the surgery,
and general symptom experience.
All participants completed the Disabilities of Arm,
Shoulder, and Hand (DASH). The DASH, developed by
the American Academy of Orthopedic Surgeons, is a self-
report questionnaire which measures upper limb symptoms
and ability to perform common functional activities in
people with musculoskeletal disorders of the upper extrem-
ity [22]. Test-retest reliability for the DASH has been
reported as r=0.96 [23]. The questionnaire has 30 items
with responses ranging from one to five. Scores are
typically converted to 0 to 100 with higher scores reflective
of greater disability. The first 21 items are questions in
which the individual rates their ability (“no difficulty, mild
difficulty, moderate difficulty, severe difficulty or unable”)
to perform specific activities, such as ability to turn a key,
prepare a meal, or make a bed. Two items ask questions
regarding the extent to which the upper extremity impair-
ment results in limitations in social activities or activities of
daily living. Of the remaining questions regarding upper
limb function, five pertain to severity of symptoms, one to
sleep interference, and the last to feelings of confidence or
usefulness. In reference to the International Classification
of Functioning, Disability and Health Model, Dixon et al.
[24] report the DASH contains five impairment items, 19
activity limitations, and three participation restriction
items.
Data analysis
Sample size estimate of 120 participants was determined
prospectively, based on an alpha level of 0.05, and power
of 0.80. This sample size estimate was based on an
estimated correlation coefficient of 0.25 for regression
analysis.
Statistical analyses were performed using SPSS statisti-
cal software (version 16, SPSS Inc, Chicago, IL). Means
and standard deviations for interval data were obtained and
unpaired t-tests for significance of differences were per-
formed for normally distributed data. Mann-Whitney
ranked sum analysis was used for non-normally distributed
interval data. Chi square was used to assess significance of
differences in proportions for nominal and categorical
variables. To compare interlimb differences between wom-
en with lymphedema and those without, analysis of
variance (ANOVA) was carried out for within and between
group differences.
Regression analysis was used to evaluate the contribu-
tion of independent variables of theoretical interest to the
J Cancer Surviv (2010) 4:167–178 169outcome measure. Multiple linear regression was selected
for normally distributed interval data. The DASH was used
as the dependent variable. Based on the Item Response
Theory method, raw DASH scores were converted to logit
scores (the natural log of the probability of obtaining a
particular set of responses versus the probability of not
obtaining that set of responses). This analysis allowed
conversion of the raw DASH scores to an authentic interval
scale.
Results
Participant characteristics
Results of 144 women were included. Of those, 73 reported
a previous diagnosis of lymphedema. Characteristics for
study participants are summarized in Table 1. The women
with lymphedema demonstrated significantly higher body
mass index, greater arm volume, more years since diagnosis
of breast cancer, greater numbers of women who had had
node dissection, and greater number of nodes removed.
During the 3 months prior to testing, more women in the
Lymphedema group reported symptoms of pain, heaviness,
ache, or strange sensations in the affected arm (68%) than
in the Non-lymphedema group (39%).
Type of breast cancer surgery was dichotomized to
breast conserving surgery (lumpectomy, segmentectomy,
quadrantectomy) and mastectomy (simple, modified radi-
cal, or radical). No differences in the number of women
were found between groups for radiation, chemotherapy, or
type of breast surgery. There were also no differences
between groups in numbers of medical comorbidities.
Ninety percent of the women had three or fewer comorbid-
ities. Overall, the most commonly reported comorbidities
were back pain (n=46), depression (n=34), and high blood
pressure (n=33).
The difference in DASH scores between the 2 groups is
presented in Table 2. Women with lymphedema scored
higher on the DASH than the women without lymphedema.
A higher DASH score is indicative of relatively greater
limitation.
Table 1 Characteristics of participants, grouped by self-report of lymphedema diagnosis
Characteristics All participants
n=144
Non-
Lymphedema
n=71
Lymphedema
n=73
Difference in
means (sd)
95% confidence
interval
Sig. (p)
Age (years) 56.33 (9.44) 55.17 (8.76) 57.47 (9.98) 2.30 (1.57) (−5.39, 0.80) 0.15
a
Body mass index 26.4 (5.54) 25.45 (4.63) 27.33 (6.22) 1.88 (0.91) (−3.68, −0.08) 0.04
a
Arm volume difference (ml) 109.9 (243.21) −7.9 (72.61) 224.5(292.16) −232.34 (35.26) (−302.5, −162.2) <0.001
a
Affected side Right/Left 67/77 29/42 38/35 0.18
b
Dominant UE R/L/ambidext. 130/11/3 64/5/2 66/6/1 0.81
b
Affected side = Dominant side 71 33 38 0.50
b
Years of education 16.69 (2.71) 17.04 (2.48) 16.33 (2.98) 0.71 (0.45) (−0.18, 1.60) 0.12
a
Days/week of exercise 3.41 (1.72) 3.51 (1.64) 3.31 (1.80) 0.21 (0.29) (−0.37, 0.77) 0.48
a
No. of women working for pay 85 41 44 0.76
b
Years since breast cancer diagnosis 6.17 (5.35) 4.94 (4.06) 7.37 (6.15) 2.43 (0.87) (−4.15, −0.72) 0.01
a
No. of women who had:
BCS
c 82 39 43 0.63
b
Mastectomy 62 32 30
Sentinel lymph node biopsy 93 54 39 0.01
b
Axillary lymph node dissection 108 46 62 <0.005
b
No. of nodes removed 10.99 (7.48) 8.59 (6.43) 13.39 (7.73) 4.80 (1.20) (−7.18, −2.43) <0.001
a
No. who received radiation therapy 107 49 58 0.15
b
No. who received chemotherapy 101 48 53 0.51
b
No. who received prior treatment for
lymphedema
81 15 66 <0.001
b
aindependent t-tests for differences in means
bChi square
cBCS: breast conserving surgery
Bold indicates statistical significance
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Significant differences in strength, range of motion, and
sensation were found between the affected and unaffected
upper extremities, and between patients with and without
lymphedema. Assessment of fine motor skills using the
Purdue Pegboard and the Finger Tapper yielded no
significant differences between upper extremities or lym-
phedema groups.
Paired t-tests were performed to assess the differences
between the affected and unaffected sides for each group.
Results are summarized in Table 3. In the Non-lymphedema
group, the affected side demonstrated less shoulder abduc-
tion strength, and less range of motion of shoulder flexion,
abduction, and external rotation, and the overall ROM score
(p<0.05) compared to the unaffected side. No other
differences between sides were observed in the Non-
lymphedema group. For the Lymphedema group, the
affected side had less strength in elbow flexion, wrist
flexion, and 2 of the 3 grip tests, which resulted in an
overall decrease in upper extremity strength compared to
the unaffected side. There was less sensitivity to Semmes-
Weinstein monofilament testing at the medial aspect of the
arm, medial forearm, and index finger in the Lymphedema
group. In addition, there was less ROM of the affected
shoulder (flexion, abduction, and ER), wrist (flexion), and
index proximal interphalangeal joint (flexion); and a lower
overall ROM score (p<0.05). The largest differences were
seen in shoulder abduction. Analysis of variance revealed
additional within and between group differences. Bilateral-
ly, women with lymphedema had less elbow flexion
strength, and less ROM in shoulder flexion, abduction,
external and internal rotation, elbow extension, and index
proximal interphalangeal flexion compared to the women
without lymphedema. These differences were most pro-
nounced in shoulder abduction ROM (Fig. 1). Moreover,
the differences between affected and unaffected sides were
greater in the women with lymphedema than in the women
without lymphedema in elbow flexion strength, in 1 of 3
grip measures, in ROM (shoulder flexion, abduction, wrist
flexion, and index proximal interphalangeal flexion) and in
4 of the 7 regions tested for light touch. The loss of range of
motion in shoulder abduction on the affected side in the
Lymphedema group was twice the loss of that seen in the
Non-lymphedema group (Fig. 1). Table 4 summarizes
significance levels for the within subjects and between
groups differences.
Regression analysis
Multiple linear regression was used to evaluate the
contribution of the predictor variables to variance in the
DASH scores. Correlation matrices were constructed for
three thematic sets of predictor variables: demographic and
symptom, objective measures of limb volume, and objec-
tive measures of UE impairments. To screen for predictors
to use in building the multiple linear regression model,
predictor variable candidates within thematic sets were
evaluated to identify those that correlated with the DASH
(the dependent variable) at r>0.20 (p<0.01). This level of
correlation was chosen based on previously reported
correlations between the DASH and various upper extrem-
ity objective measures [25]. A correlation of 0.20 represents
4% of the shared variance. The DASH scores were then
regressed on the predictors within each thematic set that
met the >0.20 criterion. Those predictors in the model that
failed to satisfy alpha <0.1 criterion were identified and
progressively removed from the model, beginning with the
variable with the highest p value. For the demographic/
symptom variable set, predictor variables of interest
consisted of age, hand dominance, if the dominant side
was the affected side, anthropometric characteristics, social
support, work history, exercise history, income, education,
comorbidities, past diagnosis of lymphedema, breast symp-
toms, and upper extremity symptoms. Predictor variables of
significance in the model were number of comorbidities
(p<0.001), subjective report of lymphedema (p=0.012),
and pain severity (p=0.020). No predictors of significance
were found in the variable set of objective measures of
volume. Significant predictors in the UE impairment set
consisted of full grip strength on the affected side (p=
0.001), and shoulder abduction ROM on the affected side
(p=0.003). The DASH was then regressed on the five final
predictors from the 3 thematic sets. The predictors again
Table 2 DASH scores
Non-lymphedema group Lymphedema group Difference in means (Mann Whitney U)
Mean (SD) Median (range) Mean (SD) Median (range)
DASH
(0–100 scale) 8.67 3.67 18.48 14.17 p<.001
(12.63) (0–7.8) (17.30) (1–76.7)
Bold indicates statistical significance
J Cancer Surviv (2010) 4:167–178 171were evaluated to determine if all met the alpha <0.1
criterion, and again the one with the highest p value was
dropped. This procedure was followed until all predictors in
the model were significant at alpha <0.1.
The predictors found to significantly contribute to
the variance of the DASH scores and be included in
the final regression model were past diagnosis of
lymphedema (p<.0.001), grip strength on the affected
upper extremity (p<0.001), shoulder abduction ROM on
the affected side (p=0.003), and number of comorbid-
ities (p<0.001). This combination of predictors resulted
in an R
2 of 0.463. Thus, the four predictor variables
explained 46.3% of the variance in the DASH scores
(Tables 5 and 6).
Table 3 Comparison of differences in upper extremity measures for women without and with lymphedema
Non lymphedema group n=71 Lymphedema group n=73
Unaffected arm versus affected arm Unaffected arm versus affected arm
UE measures Unaffected
Mean (SD)
Affected
Mean (SD)
Mean diff (95% CI) Unaffected
Mean (SD)
Affected
Mean (SD)
Mean diff (95% CI)
Purdue Pegboard time(sec) 80.2 (8.1) 80.6 (12.3) −0.4 (−3.0, 2.2) 82.4 (10.4) 82.8 (12.1) −0.3 (−3.1, 2.4)
Finger Tapper (no. of taps) 44.5 (7.6) 45.4 (7.0) −0.9 (−2.3, 0.6) 43.0 (7.5) 43.5 (6.9) −0.5 (−2.1, 1.1)
Shoulder ABD
b strength kg 12.5 (2.4) 12.1 (2.6) 0.4 (0.03, 0.8)
a 11.8 (2.5) 11.5 (4.6) 0.3 (−0.6, 1.2)
Elbow flexion strength 20.9 (4.0) 20.9 (4.2) −0.01 (−0.4, 0.4) 19.6 (3.7) 18.5 (3.8) 1.1 (0.6, 1.5)
a
Wrist flexion strength 9.4 (2.2) 9.6 (2.2) −0.2 (−0.5, 0.1) 8.9 (2.2) 9.4 (2.2) −0.4 (−0.8, −0.1)
a
Grip strength 27.5 (7.0) 26.6 (7.1) 0.9 (−0.02, 1.8) 26.6 (6.4) 25.2 (6.2) 1.4 (0.3, 2.5)
a
Key grip strength 5.6 (1.5) 5.6 (1.6) 0.1 (−0.2, 0.4) 5.5 (1.6) 5.3 (1.4) 0.2 (−0.9, 0.5)
3 point chuck grip 6.5 (1.7) 6.7 (1.8) −0.2 (−0.5, 0.1) 6.7 (1.8) 6.3 (1.7) 0.4 (0.1, 0.7)
a
All strength 82.8 (15.4) 81.6 (15.9) 1.3 (−0.3, 2.9) 79.5 (13.8) 75.8 (14.9) 3.8 (1.6, 5.9)
a
VPT
c digits (microns) 0.1 (0.10) 0.13 (0.15) −0.01 (−0.03, 0.003) 0.12 (0.08) 0.13 (0.10) −0.01 (−0.03, 0.002)
VPT radial styloid 0.5 (0.4) 0.5 (0.5) −0.03 (−0.1, 0.04) 0.5 (0.4) 0.5 (0.3) −0.1 (−0.1, 0.01)
VPT medial epic. 0.9 (0.9) 0.8 (0.9) 0.1 (−0.1, 0.2) 0.9 (0.86) 1.1 (1.08) −0.2 (−0.5, 0.1)
SWM
d web 20.5 (2.7) 20.9 (2.6) −0.4 (−1.1, 0.3) 20.04 (2.42) 20.18 (2.30) −0.2 (−0.7, 0.4)
SWM index finger 20.5 (2.4) 21.0 (2.28) −0.5 (−1.0, 0.03) 20.6 (2.67) 20.1 (2.9) 0.5 (0.04, 1.03)
a
SWM little finger 21.5 (2.5) 22.1 (2.2) −0.6 (−1.1, −0.03)
a 21.6 (2.6) 21.7 (2.7) −0.1 (−0.6, 0.5)
SWM lateral forearm 20.8 (2.5) 21.3 (2.1) −0.5 (−1.0, 0.1) 20.3 (2.2) 19.9 (2.9) 0.5 (−0.2, 1.2)
SWM medial forearm 19.8 (2.0) 19.8 (1.9) −0.04 (−0.5, 0.4) 19.3 (2.2) 18.6 (2.2) 0.7 (0.2, 1.2)
a
SWM lateral arm 20.1 (2.3) 20.1 (2.5) −0.04 (−0.6, 0.5) 19.7 (2.2) 19.4 (2.2) 0.3 (−0.1, 0.8)
SWM medial arm 19.1 (2.5) 18.9 (2.6) 0.3 (−0.3, 0.8) 19.1 (2.6) 17.4 (3.2) 1.7 (0.9, 2.5)
a
Shoulder flexion ROM
e 169 (8) 166 (9) 3.0 (1.7, 4.5)
a 167 (9) 161 (12) 6.0 (3.9, 8.2)
a
Shoulder ABD ROM 162 (19) 153 (25) 9.3 (4.8, 13.7)
a 158 (20) 140 (29) 17.5 (11.7, 23.4)
a
Shoulder ER
b ROM 93 (9) 89 (11) 3.7 (1.4, 6.0)
a 89 (10) 86 (13) 2.8 (0.3, 5.3)
a
Shoulder IR
b ROM 43 (9) 42 (10) 0.9 (−1.1, 2.9) 45 (9) 44 (10) 1.1 (−0.9, 3.2)
Elbow flexion ROM 149 (4) 150 (4) −0.5 (−1.2, −0.2) 150 (4) 149 (4) 0.8 (−0.1, 1.6)
Elbow extension ROM 2 (4) 2 (4) 0.2 (−0.4, 0.7) 0.3 (5) 0.9 (4) −0.7 (−1.4, 0.1)
Wrist flexion ROM 77 (8) 78 (7) −0.6 (−2.0, 0.8) 77 (7) 75 (7) 2.0 (0.8, 3.1)
a
Wrist extension ROM 74 (7) 73 (8) 0.3 (−0.8, 1.3) 72 (7) 71 (8) 1.5 (−0.1, 3.2)
Index PIP
b ROM 114 (6) 114 (4) −0.3 (−1.3, 0.7) 112 (9) 110 (7) 1.6 (0.01, 3.2)
a
Overall ROM score 882 (40) 866 (54) 15.9 (8.3, 23.4)
a 870 (47) 836 (62) 32.7 (22.2, 43.2)
a
ap<0.05
bABD: abduction; ER: external rotation; IR: internal rotation; PIP: proximal interphalangeal joint
cVibration perception threshold (in microns)
dSemmes Weinstein Monofilaments (number of correct responses)
eRange of motion (in degrees)
Bold indicates statistical significance
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The results of this study supported our hypotheses.
Following breast cancer treatment, upper extremity impair-
ments are present on the side of the breast cancer treatment.
Furthermore, our study demonstrates that women with
lymphedema demonstrated greater impairments than wom-
en without lymphedema.
Range of motion
Interlimb differences in upper extremity ROM were most
notable for shoulder abduction. This finding may indicate a
need for early therapeutic intervention to improve upper
extremity biomechanics in shoulder elevation in women
treated for breast cancer. Our findings are consistent with
those of Thomas-MacLean et al. who found both restricted
shoulder abduction ROM (<170° on the side of treatment) in
205 out of 347 women 6–12 months following breast cancer
treatment, and an interlimb difference of greater than 10° in
41% of the women [16]. Deficits in ROM following breast
cancer treatment may be the result of postoperative scar
tissue formation, radiation-induced fibrosis, protective pos-
turing bringing the shoulders forward, disuse, and/or pain.
Limitations in shoulder abduction may interfere with daily
activities including reaching behind the head to wash or
comb one’s hair, or movements requiring maximal shoulder
elevation such as reaching items high on a shelf. Our study
findings indicated that reductions in shoulder ROM were
associated with greater upper extremity disability (higher
DASH scores), as became apparent with regression analysis.
Interlimb differences in shoulder abduction were greater
in women with lymphedema compared to those without
(18° versus 9°). Our data are in agreement with the findings
of Kwan et al. who compared 3 groups of women following
breast cancer treatment: those with no upper extremity
symptoms (n=51); those with symptoms but no signs of
lymphedema (n=47); and those with lymphedema (n=14).
Interlimb differences in abduction ROM were 5.9°, 19.9°,
and 31.1°, respectively [26]. More aggressive breast cancer
treatments, such as mastectomy versus breast conserving
surgery, and axillary node dissection versus sentinel node
biopsy, are associated with greater deficits in shoulder
abduction ROM [27–29]. Women who undergo more
aggressive treatment for their breast cancer and women
who develop lymphedema may require more vigilant
musculoskeletal screening following treatment to preserve
maximal shoulder elevation.
Strength
Strength differences between the two groups of women
were found primarily in elbow flexion. Compared to the
women without lymphedema, reduction of elbow flexion
strength was seen bilaterally in the women with lymphe-
dema, with the deficit greater on the affected side. Elbow
flexion strength was significantly correlated with the DASH
item related to carrying objects over 10 lbs. Past advice for
women with lymphedema included avoidance of lifting or
carrying moderately heavy items with the affected upper
extremity [30, 31]. Activity avoidance advice may be a
disservice, as upper extremity strength may worsen over
time with decreased use, consistent with our findings of
reduced elbow flexion and grip strength in women with
lymphedema. Though the interlimb difference in grip
strength (1.37 kg) between groups did not reach statistical
significance, grip strength did significantly contribute to the
variance in DASH scores.
Pain and sensation
The women with lymphedema more frequently reported
upper extremity symptoms such as pain, ache, numbness, or
heaviness in the arm. Sensory disturbances in the affected
upper extremity following breast cancer treatment may
result from nerve damage during surgery or following
radiation, neuropathy due to chemotherapy, or perhaps
lymphedema. The women with lymphedema demonstrated
reduced sensation in the medial arm, which may be the
result of trauma to the intercostobrachial or other nerves
during axillary node dissection, resulting in subsequent
sensory loss. Development of chronic pain following
mastectomy has been associated with damage to the
intercostobrachial nerve [32]. In the current study, there
was a statistically significant but weak correlation between
pain and sensory loss; women with less medial arm
sensation more frequently reported pain in the upper
extremity. However, there was a moderate correlation
between breast pain and the DASH (r=0.50) and between
Figure 1 Shoulder abduction range of motion (in degrees).
J Cancer Surviv (2010) 4:167–178 173arm pain and the DASH (r=0.49). In light of this, and that
self-reported symptoms of heaviness, numbness, and
swelling have been associated with and suggested as
possible early indicators for lymphedema [33], lymphe-
dema management should include assessment of pain,
heaviness, tightness, or swelling in the affected upper
extremity, in addition to circumference measurement. This
is supported by published clinical practice guidelines [34].
Body mass index
Body mass index was found to be significantly higher in the
women with lymphedema than those without. Twenty-one of
the 31 women who had a BMI over 30, and thus would be
considered to be “obese”, were in the Lymphedema group.
These findings are in agreement with extant literature, in
which obesity and weight gain following breast cancer
Table 4 Summary of significance of differences between upper extremities, and differences between groups (Analysis of Variance)
Within subjects contrasts: main
effect of side
Between subjects effects: main effect of
lymphedema
Interaction effect: side and
lymphedema
Was the difference between sides
significant, regardless of group?
Was the difference between groups
significant, averaged across both arms?
Were the differences greater in
the lymphedema group?
pp p
Purdue Pegboard time(sec) 0.68 0.16 0.95
Finger Tapper (no. of taps) 0.23 0.13 0.73
Shoulder ABD
b strength kg 0.16 0.16 0.82
Elbow flexion strength 0.001
a 0.004 0.001
Wrist flexion strength 0.01 0.25 0.32
Grip strength 0.02 0.27 0.51
Key grip strength 0.16 0.53 0.51
3 point chuck grip 0.34 0.65 0.002
All strength <0.001 0.06 0.07
VPT
c digits (microns) 0.03 0.69 0.98
VPT radial styloid 0.07 0.69 0.66
VPT medial epic. 0.32 0.22 0.06
SWM
d web 0.20 0.10 0.60
SWM index finger 0.94 0.40 0.01
SWM little finger 0.09 0.57 0.20
SWM lateral forearm 1.0 0.01 0.03
SWM medial forearm 0.07 0.01 0.04
SWM lateral arm 0.42 0.09 0.30
SWM medial arm 0.004 0.04 0.00
Shoulder flexion ROM
e <0.001 0.02 0.02
Shoulder abduction ROM <0.001 0.01 0.03
Shoulder ER
b ROM <0.001 0.03 0.59
Shoulder IR
b ROM 0.15 0.15 0.86
Elbow flexion ROM 0.63 0.91 0.02
Elbow extension ROM 0.29 0.03 0.07
Wrist flexion ROM 0.14 0.13 0.01
Wrist extension ROM 0.07 0.12 0.20
Index PIP
b ROM 0.16 0.01 0.05
Overall ROM score <0.001 0.01 0.01
ap<0.05
bABD: abduction; ER: external rotation; IR: internal rotation; PIP: proximal interphalangeal joint
cVibration perception threshold (in microns)
dSemmes Weinstein Monofilaments (number of correct responses)
eRange of motion (in degrees)
Bold indicates statistical significance
174 J Cancer Surviv (2010) 4:167–178treatment have been associated with the development of
lymphedema [35]. There is also evidence that high BMI and
lack of vigorous physical activity may be associated with
increased breast cancer risk [36]. Furthermore, it is well
known that high BMI is associated with increased risk of
chronic diseases such as cardiovascular disease and diabetes.
These findings suggest that weight management may be an
important component of rehabilitation following breast
cancer treatment to aid in the prevention and management
of lymphedema, as well as to reduce the risk of cancer
recurrence and the development of other chronic illnesses.
DASH
Women with a previous diagnosis of lymphedema scored
higher on the DASH, indicating greater limitation in upper
extremity activities compared to the women without a
history of lymphedema. Although the DASH scores for the
women in this study indicated a relatively high self-
reported level of upper extremity physical function, there
was a statistically significant difference (10 points) between
the Lymphedema and Non-lymphedema groups. A 10-point
difference has been suggested as the minimal important
change in DASH scores following treatment of upper
extremity musculoskeletal impairments [22].
Our findings are consistent with those of Dawes et al.
who examined scores for the DASH questionnaire for a
group of women following breast cancer surgery. Of the
204 respondents, 72 (35%) reported more than one
symptom associated with lymphedema. These women
had significantly higher scores on the DASH compared
to non-symptomatic women, indicative of greater limita-
tions in upper extremity function. Clinical assessment of a
sample of 50 of the women with lymphedema symptoms
yielded statistically significant compromise in manual
dexterity, grip strength, and scores on the Medical
Outcome Study Short Form 36 Physical Component Scale
[37]. We found similar impairments in strength in the
women in our study.
Grip strength and shoulder abduction ROM on the
affected side, number of comorbidities, and previous
diagnosis of lymphedema significantly contributed to the
variance in the DASH scores. Interestingly, in spite of the
contribution of past diagnosis of lymphedema, neither arm
volume (calculated from circumference) nor impedance
ratios (from bioimpedance spectroscopy) contributed to the
variance in the DASH scores. This finding is also consistent
with the findings of Dawes et al. [37].
Most of the women in the Lymphedema group had mild
lymphedema. Only four women had volume differences
greater than 750 ml. This is consistent with the distribution
of lymphedema categories in the 3 year incidence of
lymphedema found by Norman et al. [11], and may be
reflective of lymphedema severity in the general breast
cancer-related lymphedema population. Furthermore, all
but seven of the women in our study who were previously
diagnosed with lymphedema had received lymphedema
treatment. Previous treatment included education, compres-
sion, remedial exercise, manual lymph drainage, bandaging,
and instruction in self care and management. It is possible
Table 5 DASH regression summary
Change Statistics
Model R R Square R Square
Change
F Change Sig. F Change
p
1. Subject diagnosed with lymphedema .378 .143 .143 23.269 .000
2. Subject diagnosed with lymphedema, grip strength affected side .592 .351 .208 44.646 .000
3. Subject diagnosed with lymphedema, grip strength affected side, shoulder
abduction ROM affected side
.620 .385 .034 7.618 .007
4. Subject diagnosed with lymphedema, grip strength affected side, shoulder
abduction ROM affected side, Number of comorbidities
.681 .463 .078 19.977 .000
Table 6 Coefficients table
B Std. error Beta t Sig 95% CI for B
(Constant) .466 .699 0.668 0.51 −.915, 1.848
subject diagnosed with lymphedema .911 .212 .277 4.302 <.001 .492, 1.330
shoulder abduction ROM affected side −.012 .004 −.202 −3.072 0.003 −.020, −.004
grip strength affected side −.038 .007 −.341 −5.099 <.001 −.052, −.023
Number of comorbidities .320 .072 .291 4.470 <.001 .178, .461
J Cancer Surviv (2010) 4:167–178 175these women chose to limit use of the affected upper
extremity as part of the lymphedema management, regard-
less of current limb volume. This behavior of limited use
may have contributed to higher DASH scores in this group.
Actual volume of lymphedema does not explain concurrent
functional arm limitation and may not be reflective of the
true impact of chronic lymphedema.
Overall, the women in this study demonstrated relatively
low scores on the DASH in spite of significant upper
extremity impairments. This suggests that upper extremity
impairment does not necessarily preclude women from
achieving a fairly high level of activity. While working to
restore strength and range of motion, rehabilitation pro-
fessionals can also guide and encourage return to safe
activity following breast cancer treatment in spite of these
limitations.
Correlation between the DASH and objective measures
of upper extremity physical impairments and limitations
were variable, from poor to moderate. The highest
correlations were found for shoulder abduction ROM and
strength, elbow flexion strength, and grip strength, on the
affected side (r=0.35 to 0.50). As previously noted, pain in
the breast and arm were also moderately correlated with the
DASH. With these relatively modest correlations, it appears
that factors other than range of motion and strength
influence actual task performance. We did not find
significant correlations between the DASH and demograph-
ic variables such as age, or body mass index, nor current
work or exercise history. Inclusion of objective measure-
ment and self report of physical limitations may help direct
clinical decision making and referral to appropriate health
care providers. Those patients with self report of physical
activity limitations, without any evidence of pain or
objective physical impairments, may benefit from further
assessment or referral to a behavioral health specialist.
Our study highlights the degree of upper extremity
impairment, and the impact of these impairments, medical
comorbidities, and lymphedema on upper extremity phys-
ical function in women following breast cancer treatment,
and underscores the need for increased exercise and
physical activity in this group. Studies of exercise inter-
ventions are beginning to emerge in the literature. Ahmed
et al., in a randomized controlled trial of women with and
without breast-cancer-related lymphedema, compared twice
weekly weight training (n=23) to a non-exercise control
group (n=22). The gradually progressive strengthening
program resulted in significantly improved bench press
strength in the exercise group, and there was no evidence of
new or worsening lymphedema [30]. More recently, 32
women with breast-cancer-related lymphedema participated
in a single blind randomized control study designed to
evaluate the effects of aerobic and weight training exercises
on lymphedema. Exercise did not exacerbate lymphedema,
and two of the women in the exercise group had no
evidence of lymphedema at the conclusion of the study
[15]. These recent studies suggest that increased activity
and exercise is beneficial and safe for women with breast-
cancer-related lymphedema.
Limitations
We provide evidence that lymphedema is associated with
greater reduction in upper extremity mobility, strength, and
sensation. However, due to the cross sectional design
employed in this study, we cannot conclude that the
presence of lymphedema was the cause of these reductions.
The DASH has been used previously as a measure of
upper extremity function in women with breast cancer;
however, the DASH has not as yet been validated in this
group. The DASH had a floor effect in our study, which
may have influenced the responsiveness of the instrument
to differences in higher functioning women who occupy the
lower range of scores on the scale.
While we did find a significant difference in DASH
scores between groups, perhaps a more responsive instru-
ment would highlight more subtle differences in the higher
functioning participants. The correlations were low to
moderate (between −0.18 and −0.50 in the present study)
between objective measures of physical impairments such
as ROM, strength, fine motor coordination and the self-
report measures of physical symptoms and functional
activities (i.e., the DASH). These findings are consistent
with the results of other investigators [38, 39]. Performance
of functional tasks is influenced by psychosocial and
environmental factors, not all of which were addressed in
the present study. It appears that self report and objective
measures of upper extremity physical impairments and
performance activities may not be entirely, or exclusively,
reflective of one another and both may need to be included
for optimal assessment of physical function. Further
investigation of upper extremity physical functioning
questionnaires for use in this population is warranted.
Conclusion
Our study indicates that following breast cancer treatment,
women with and without lymphedema present with upper
extremity impairments. Women with lymphedema more
frequently report pain, demonstrate bilateral impairments in
shoulder ROM and upper extremity strength compared to
women without lymphedema, and present with greater
restrictions in upper limb activities. Each of these limi-
tations is amenable to rehabilitation interventions. Based on
the results of this study, physical rehabilitation should be
included in the management of sequelae following breast
176 J Cancer Surviv (2010) 4:167–178cancer treatment. Assessment and treatment of breast
cancer survivors should address limb volume (and volume
changes), bilateral upper extremity ROM and strength,
sensation and pain, body mass index, and presence of other
medical comorbidities. It is important to keep in mind that
complications from breast cancer treatment, such as
lymphedema and fibrosis, may not be apparent for months
to years after the end of the cancer treatment. In light of the
growing numbers of breast cancer survivors, and the
likelihood for the development of impairments and activity
limitations post cancer treatment, it is imperative for health
care providers, particularly physical and occupational
therapists, to be aware of the unique problems faced by
this population and advocate for prevention and evidence-
based intervention.
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